Bristol-Myers Squibb Co. (NYSE:BMY) dropped 15.2% on Friday . The company traded as low as $61.56 and last traded at $63.90, with a volume of 61,615,908 shares trading hands. The stock had previously closed at $75.32.

Several research analysts have recently commented on BMY shares. Vetr downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating and set a $60.30 price target on the stock. in a report on Thursday, April 14th. Berenberg Bank reaffirmed a “buy” rating and set a $80.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, April 22nd. Credit Suisse Group AG reaffirmed an “overweight” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 26th. Leerink Swann reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, April 27th. Finally, Barclays PLC lifted their price objective on Bristol-Myers Squibb from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, April 29th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $74.98.

The company’s 50-day moving average is $73.96 and its 200-day moving average is $68.53. The company has a market capitalization of $105.73 billion and a price-to-earnings ratio of 37.01.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. During the same period last year, the firm earned $0.53 earnings per share. The business had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. The company’s quarterly revenue was up 17.2% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb Co. will post $2.64 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.40%.

In other news, CFO Charles A. Bancroft sold 30,201 shares of the business’s stock in a transaction on Friday, May 20th. The shares were sold at an average price of $70.79, for a total transaction of $2,137,928.79. Following the completion of the transaction, the chief financial officer now owns 184,694 shares of the company’s stock, valued at $13,074,488.26. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lamberto Andreotti sold 23,200 shares of the business’s stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $72.14, for a total transaction of $1,673,648.00. Following the transaction, the director now directly owns 403,094 shares of the company’s stock, valued at approximately $29,079,201.16. The disclosure for this sale can be found here.

Other large investors recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 100,977,126 shares of the biopharmaceutical company’s stock valued at $6,946,217,000 after buying an additional 2,396,947 shares during the period. Jennison Associates LLC boosted its stake in shares of Bristol-Myers Squibb by 19.2% in the fourth quarter. Jennison Associates LLC now owns 27,739,860 shares of the biopharmaceutical company’s stock valued at $1,908,225,000 after buying an additional 4,462,075 shares during the period. Brown Advisory Inc. boosted its stake in shares of Bristol-Myers Squibb by 5.4% in the fourth quarter. Brown Advisory Inc. now owns 8,541,624 shares of the biopharmaceutical company’s stock valued at $587,578,000 after buying an additional 433,894 shares during the period. Eaton Vance Management boosted its stake in shares of Bristol-Myers Squibb by 2.6% in the fourth quarter. Eaton Vance Management now owns 4,013,709 shares of the biopharmaceutical company’s stock valued at $276,103,000 after buying an additional 102,493 shares during the period. Finally, Westfield Capital Management Co. LP boosted its stake in shares of Bristol-Myers Squibb by 2,141.4% in the fourth quarter. Westfield Capital Management Co. LP now owns 2,921,174 shares of the biopharmaceutical company’s stock valued at $200,948,000 after buying an additional 2,790,844 shares during the period.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.